Soma Gen-Ichiro, Oda Masataka, Tjhin Vindy Tjendana, Kohchi Chie, Inagawa Hiroyuki
Control of Innate Immunity, Technology Research Association, Takamatsu, Kagawa, Japan.
Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Front Immunol. 2025 Mar 31;16:1563484. doi: 10.3389/fimmu.2025.1563484. eCollection 2025.
Lipopolysaccharide (LPS), also known as an endotoxin, is derived from Gram-negative bacteria. The intravenous administration of LPS induces an inflammatory response and causes systemic inflammation, such as cytokine storm. Gram-negative bacteria that produce LPS are found in the environment and digestive tract. The mucous membrane, the primary barrier between the interior of the body and the external environment, is constantly exposed to LPS. Moreover, no toxicity is observed when administering LPS through the mucous membranes of the mouth or skin. The presence of LPS in the mucous membranes is necessary not only for maintaining health but also for inducing preventive and therapeutic effects against multiple diseases when administered orally or topically. LPS is an environmental substance that is useful when administered to mucous membranes. The general information emphasizes the role of LPS as an inflammatory substance that occurs when administered intravenously. Therefore, the valuable role of LPS is unknown. Thus, mucosal administration of LPS has received little attention, and the mechanism underlying the expression of its beneficial effects has not been fully elucidated. We proposed a comprehensive concept, the "macrophage network," which proposes a regulatory system in which the mucosa receives environmental information, membrane-bound cytokines are expressed in phagocytes (macrophages), and these macrophages migrate distally to exert effects, such as anti-inflammatory and tissue repair effects, on distal tissues through cell-to-cell communication (juxtacrine signaling) with tissue macrophages. This macrophage network is effective not only for preventing and treating diseases but also for increasing the efficacy of pharmaceuticals. This review aims to investigate the preventive and therapeutic effects of oral and transdermal administration of LPS on various diseases and present an introduction to the concept of the macrophage network and the latest findings.
脂多糖(LPS),也被称为内毒素,源自革兰氏阴性菌。静脉注射LPS会引发炎症反应并导致全身炎症,如细胞因子风暴。产生LPS的革兰氏阴性菌存在于环境和消化道中。黏膜作为身体内部与外部环境之间的主要屏障,不断接触LPS。此外,通过口腔或皮肤黏膜施用LPS时未观察到毒性。黏膜中LPS的存在不仅对维持健康是必要的,而且在口服或局部施用时对多种疾病具有预防和治疗作用。LPS是一种环境物质,当施用于黏膜时是有益的。一般信息强调LPS作为静脉注射时出现的炎症物质的作用。因此,LPS的重要作用尚不清楚。因此,LPS的黏膜给药很少受到关注,其有益作用表达的潜在机制尚未完全阐明。我们提出了一个全面的概念,即“巨噬细胞网络”,它提出了一种调节系统,其中黏膜接收环境信息,膜结合细胞因子在吞噬细胞(巨噬细胞)中表达,并且这些巨噬细胞向远端迁移,通过与组织巨噬细胞的细胞间通讯(旁分泌信号传导)对远端组织发挥抗炎和组织修复等作用。这个巨噬细胞网络不仅对疾病的预防和治疗有效,而且对提高药物疗效也有效。本综述旨在研究口服和经皮施用LPS对各种疾病的预防和治疗作用,并介绍巨噬细胞网络的概念和最新发现。